Publish time: 2022-08-29 00:00:00
10A-1100824
Patent Pending
Bacterial vaginosis (BV) is a common condition in reproductive-aged women, with a worldwide prevalence of over 30%. Current first-line antibiotic regimens are associated with a high recurrence rate for BV that may be due to an inability of antibiotics to effectively eradicate bacterial biofilms. The current first-line antibiotics, metronidazole and clindamycin, cannot inhibit many BV-associated bacteria. G. vaginalis and BV-associated bacteria often form a complex polymicrobial bio-structure in the BV biofilm, which is not only composed of anaerobic bacteria. It has been found that some aerobic bacteria, such as Streptococcus spp. and Escherichia coli, are also involved in BV pathogenesis. After the patient receives antibiotic treatment, co-existing microbes that are not sensitive to the antibiotics can become dominant species within the human vaginal microbiota. For example, the side effect of antibiotic treatment is vaginal candidiasis. When patients suffer from vaginitis repeatedly, they are more likely to experience sexually transmitted infections (STI), such as trichomoniasis or human immunodeficiency virus (HIV), making it difficult to restore a healthy environment. Therefore, new treatment strategies are needed for BV treatment. In order to improve treatment efficacy for BV, this technology develops a bactericidal combination with therapeutic potential for BV.
This technology is an TP4 microbicide formulation with therapeutic potential for BV, and its advantages are as follows:
- Nile tilapia piscidin 4 (TP4) has a selective bactericidal activity for BV-associated bacteria and does not affect healthy human vaginal lactobacilli.
- TP4 rapidly kills G. vaginalis with low spontaneous resistance frequency.
- TP4 exhibits broad-spectrum antimicrobial and antibiofilm activity against BV-associated bacteria.
- TP4 peptide combined with chelating agent disodium EDTA and chitosan promotes eradication of biofilms formed by BV-associated bacteria.
- Bacterial Vaginosis
- Vulvovaginal Candidiasis
- Trichomoniasis
- Atrophic vaginitis
- Sexually transmitted infections
Jyh-Yih Chen and Wen-Chun Lin
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

A cationic amphipathic TP4 peptide-based antimicrobial formulation promotes eradication of bacterial vaginosis-associated bacterial biofilms